Pharmaceuticals News and Research

RSS

Designer RNA fights high cholesterol, medical researchers find

Small, specially designed bits of ribonucleic acid (RNA) can interfere with cholesterol metabolism, reducing harmful cholesterol by two-thirds in pre-clinical tests, according to a new study by researchers at UT Southwestern Medical Center in collaboration with Alnylam Pharmaceuticals and the Massachusetts Institute of Technology.

11 Aug 2008

New treatment in the pipeline for leukaemia and rheumatoid arthritis

Australian scientists believe they are well on the way to developing a new treatment for leukaemia and inflammatory diseases such as rheumatoid arthritis and asthma.

10 Aug 2008

Researchers find a cancer-inhibiting cyanobacteria that grows on coral reefs

University of Florida College of Pharmacy researchers have discovered a marine compound off the coast of Key Largo that inhibits cancer cell growth in laboratory tests, a finding they hope will fuel the development of new drugs to better battle the disease.

10 Aug 2008

Watson Pharmaceuticals announces limited recall of Fentanyl transdermal patches

Watson Pharmaceuticals, Inc. has announced that one lot of 75 mcg/hr Fentanyl Transdermal System patches sold in the United States is being voluntarily recalled from wholesalers and pharmacies.

10 Aug 2008

First cigarette "buzz", addiction linked to gene

Anyone who has ever tried smoking probably remembers that first cigarette vividly. For some, it brought a wave of nausea or a nasty coughing fit. For others, those first puffs also came with a rush of pleasure or "buzz."

10 Aug 2008

Cancer Research UK expresses 'deep concern' on kidney cancer drug decision

Cancer Research UK - the largest publicly funded research charity in the UK - wants to see the way NICE review the value of drugs altered for rare diseases, such as this type of kidney cancer, where clinical benefit is proven but evidence is limited.

8 Aug 2008

Discovery of vital key to cancer

University of Manchester scientists have uncovered the 3D structure of Mps1 - a protein that regulates the number of chromosomes during cell division and thus has an essential role in the prevention of cancer - which will lead to the design of safer and more effective therapies.

From The University of Manchester 6 Aug 2008

Chlamydia treatment in UK pharmacies will deliver convenient care for patients

Today's decision by the Medicines and Healthcare products Regulatory Agency (MHRA) to approve the reclassification of azithromycin for the treatment of chlamydia infection will mean convenient and effective care for patients, said the Royal Pharmaceutical Society of Great Britain (RPSGB).

5 Aug 2008

A new target for malaria drugs

The malaria parasite has waged a successful guerrilla war against the human immune system for eons, but a study in this week's Journal of Biological Chemistry has exposed one of the tricks malaria uses to hide from the immune proteins, which may aid in future drug development.

4 Aug 2008

Lilly reaffirms $3.00 per share purchase offer for SGX Pharmaceuticals

Eli Lilly and Company today reaffirmed that its $3.00 per share purchase offer for SGX Pharmaceutical, Inc. represents its best and final offer for the San Diego-based biotechnology company.

4 Aug 2008

Mexico lifts regulation requiring AIDS drug companies to have manufacturing plants in Mexico in order to sell generics

On the day of the opening ceremonies of the XVII International AIDS Conference in Mexico City, President Felipe Calderon announced his plans to lift a Mexican Ministry of Economy requirement that pharmaceutical companies operating in Mexico must have a manufacturing plant in that country in order to use or sell generic versions of their lifesaving AIDS and other drugs in Mexico.

4 Aug 2008

Fatal flaws in the way new drugs are tested and marketed

Americans are likely to be exposed to unacceptable side effects of FDA-approved drugs such as Vioxx in the future because of fatal flaws in the way new drugs are tested and marketed, according to research to be presented at the annual meeting of the American Sociological Association (ASA).

3 Aug 2008

Merck announces significant price cuts on two of its AIDS drugs, Stocrin and Isentress

As more than 20,000 people from around the world gather this weekend for the start of the XVII International AIDS Conference in Mexico City, AIDS Healthcare Foundation (AHF) the US-based NGO which provides HIV/AIDS medical care and/or services to more than 79,000 individuals in 20 countries worldwide-including at four free treatment clinics in Mexico-commended Merck & Company (known as Merck, Sharp & Dohme in Mexico) over price cuts on two of its key AIDS drugs in Mexico which were announced yesterday before Sunday's opening of the AIDS conference.

3 Aug 2008

Barr confirms Xyzal tablet patent challenge

Barr Pharmaceuticals, Inc. has confirmed that its subsidiaries, Barr Laboratories, Inc. and PLIVA-Hrvatska D.O.O., have initiated a challenge of the patent listed by UCB Inc. in connection with its Xyzal(R) Tablets (levocetirizine dihydrochloride), 5mg.

31 Jul 2008

A counter to counterfeit drugs

The counterfeiting of medicines has been known of since around 1990 and is a growing problem-in both developing and developed countries. Counterfeit medicines are estimated as more than 10% of the global medicines market and in some developing countries it is thought to be as high as 50%. One prediction is that global counterfeit drug sales will reach $75 billion by 2010.

30 Jul 2008

FDA seizes more than $24 Million in unapproved new drugs

Representatives of the U.S. Food and Drug Administration and the U.S. Marshals Service today seized $24.2 million worth of unapproved new drugs from KV Pharmaceutical Company of St. Louis, Mo. Agents acted after United States Attorney Catherine L. Hanaway filed a civil forfeiture suit and obtained a warrant to seize the unapproved new drug products being made by KV Pharmaceutical.

30 Jul 2008